My Healing CommunityIntegrative Oncology Field Guide

Sulforaphane Plus Fulvestrant: Research Summary for ER+ Breast Cancer

A review of the preclinical and clinical evidence — including the STEM trial — on combining sulforaphane (as SFX-01) with fulvestrant in ER-positive metastatic breast cancer.

Sulforaphane (SFN) — the isothiocyanate found in broccoli sprouts and cruciferous vegetables — and fulvestrant (Faslodex), a selective estrogen receptor degrader (SERD) used in ER-positive metastatic breast cancer, have been studied together in preclinical and early clinical settings, primarily using a stabilised, bioavailable form of sulforaphane called SFX-01. The combination targets endocrine-therapy resistance and cancer stem-like cell activity, with one Phase II trial (STEM) showing measurable, though modest, clinical benefit when SFX-01 was added to fulvestrant in patients already progressing on it.

How Fulvestrant Works

Fulvestrant is a complete estrogen receptor antagonist that binds ERα with high affinity, blocks receptor dimerization and both activation domains (AF-1 and AF-2), and accelerates ER protein degradation via the ubiquitin-proteasome pathway, fully shutting down estrogen-driven transcription. Unlike tamoxifen, which retains partial agonist activity, fulvestrant has no agonist effects, making it a preferred second-line endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer.

How Sulforaphane Interacts With ER Signaling

Independent of fulvestrant, sulforaphane itself downregulates ERα protein in MCF-7 breast cancer cells, partly by suppressing ERα transcription and partly by promoting proteasome-mediated ERα protein degradation — a mechanism that overlaps conceptually with fulvestrant's degrader action. Some studies find SFN reduces ERα mRNA only at higher concentrations (around 30 μM), while other formulations (R-sulforaphane) affect ERα transcript without changing protein levels, indicating dose- and isomer-dependent effects that are not fully consistent across studies. Sulforaphane is also reported to support estrogen detoxification by upregulating phase 2 detoxification enzymes.

The Key Combination Study: SFX-01 Plus Fulvestrant

The most direct evidence on this pairing comes from a 2020 Oncogene paper by Simões et al., which tested SFX-01 (a stabilised, more bioavailable sulforaphane formulation) combined with fulvestrant in ER+ patient-derived xenograft (PDX) models and patient samples.

  • Fulvestrant alone paradoxically increased mammosphere formation efficiency and aldehyde dehydrogenase (ALDH)-positive cancer stem-like cell activity in PDX tumours, a known driver of endocrine resistance.

  • Adding SFX-01 reversed this stem-cell enrichment and reduced tumor-initiating cell frequency in secondary transplants.

  • Mechanistically, fulvestrant (and tamoxifen) induced STAT3 phosphorylation in tumor cells; SFX-01 suppressed phospho-STAT3 and was shown to directly bind STAT3 in patient and PDX samples, inhibiting downstream stemness genes MUC1 and OSMR.

  • In the BB3RC31 PDX model, SFX-01 plus fulvestrant reduced spontaneous lung micrometastases by 50%, an effect not seen when SFX-01 was combined with tamoxifen in that same model, suggesting the fulvestrant pairing may be particularly effective at blocking metastatic colonisation in sensitive tumours.

This work established a rationale: SFN/SFX-01 doesn't just add antiproliferative effects, it specifically counteracts a resistance mechanism (STAT3-driven stem-like cell expansion) that fulvestrant itself can inadvertently activate.

Clinical Trial Evidence: The STEM Trial

Based on this preclinical rationale, Evgen Pharma ran the STEM trial (NCT02970682), an open-label Phase II study adding SFX-01 (300 mg twice daily) to whichever endocrine therapy — aromatase inhibitor, tamoxifen, or fulvestrant — a patient's ER+/HER2- metastatic breast cancer had already progressed on.

Metric

Result

Overall clinical benefit rate (CBR) at 24 weeks

~24–26% (12/46 patients)

Objective response rate

4.3% (2/46 patients)

CBR specifically with fulvestrant + SFX-01

1/7 patients (14%)

CBR with tamoxifen + SFX-01

4/8 patients (50%)

CBR with aromatase inhibitor + SFX-01

7/28 patients (25%)

Median duration of clinical benefit

9.0 months (range 5.9–17.0 months)

Safety

Well tolerated; main side effects were indigestion (~25%) and nausea (~20%), no severe drug-related AEs

Both primary endpoints (clinical benefit rate and safety/tolerability) were met across the trial as a whole. Notably, the fulvestrant-specific arm had the smallest sample size (n=7) and the lowest response rate of the three combinations, while tamoxifen and aromatase inhibitor arms performed better — meaning that although the fulvestrant pairing is mechanistically well-supported preclinically, the clinical signal for that specific combination was weaker than for the other endocrine partners in this small trial. Five patients overall stayed on SFX-01 combination therapy for over a year without progression, and the sponsor concluded that further development in metastatic breast cancer was warranted.

Just one MCS Formulas Broccoli Ultra, Sulforaphane capsule contains 15mg of free & stabilised Sulforaphane.
Most supplements deliver the precursor of free Sulforaphane, called Sulforaphane Glucosinolate.
Visit the our Trusted Suppliers and Disocunts page to learn more.

Broader Context: Sulforaphane's Anticancer Mechanisms

Beyond the fulvestrant-specific data, sulforaphane has wide-ranging anticancer activity relevant to breast cancer that likely underlies its synergy with endocrine therapy: it increases reactive oxygen species and oxidative stress selectively in cancer cells, promotes apoptosis, arrests cells at the G2/M checkpoint, inhibits histone deacetylases (HDACs), and modulates Nrf2 antioxidant signalling. It has also shown synergy with other chemotherapeutic and dietary agents (gemcitabine, paclitaxel, genistein, sodium butyrate), reinforcing its general role as a "sensitiser" that can enhance other treatments' effects while limiting resistance-related pathways.

Sulforaphane may also influence the immune environment around a tumour—not simply by “boosting immunity,” but by changing the balance between cancer-killing cells and the cells and signals that restrain them. Experimental studies have reported reduced suppression by myeloid-derived suppressor cells (MDSCs), changes in PD-1/PD-L1 inhibitory signalling, and improved T-cell-mediated tumour killing. These effects suggest another possible route through which sulforaphane could support an anticancer response.

See our companion report, Sulforaphane and the Anticancer Immune Response: Beyond “Boosting Immunity”

Practical Takeaways and Limitations

Current evidence supports a specific, mechanistically grounded rationale for combining sulforaphane (as SFX-01) with fulvestrant — namely reversing fulvestrant-induced cancer stem cell activity via STAT3 inhibition — but clinical data remain limited to one small, open-label Phase II trial without a placebo comparator, and the fulvestrant subgroup was the smallest and weakest-responding arm. Standard dietary sulforaphane (e.g., from broccoli sprouts) has much lower and more variable bioavailability than the stabilised SFX-01 formulation used in these studies, so results from SFX-01 trials should not be assumed to directly translate to all supplements on the market. No large randomized controlled trial has yet confirmed whether adding sulforaphane/SFX-01 to fulvestrant improves progression-free or overall survival compared with fulvestrant alone.

Study Group Members SFN Dosing and Sourcing Discussion

The group's trusted supplier of the highest purity and most bioavailable compounds for cancer patients makes a unique supplement called Broccoli Ultra, that contains 15mg of free Sulforaphane per capsule (equiv. to 375mg per capsule of sulforaphane glucosinolate found in other brands/capsules).

Taking 6 capsules (3 twice a day with food) of Broccoli Ultra, per day provides 90mg free Sulforaphane (or the equiv. of 2,250mg of sulforaphane glucosinolate found in other brands/capsules). Some patients might be aiming for higher dosing depending on their treatment aims.

Linked Research pages - coming soon

References

On this page